On April 23, we suggested investors take a bullish posture on NVO, the maker of Ozempic (a popular diabetes therapy) and Wegovy (the popular weight loss drug). This article is for paid members - please login or subscribe for access. Username Password Remember Me Forgot Password Share: Mark W. Guthner, CFA Previous Post Apple Inc: AAPLNext PostDollar General: DG You Might Also Like Report McMoRan: FCX May 24, 2022 Netflix: Revealing the Man Behind the Curtain January 21, 2022 Federal Express (FDX): Back in the Dog House October 30, 2021
You Might Also Like Report McMoRan: FCX May 24, 2022 Netflix: Revealing the Man Behind the Curtain January 21, 2022 Federal Express (FDX): Back in the Dog House October 30, 2021
